Education
About Us
Working with TipRanks
Follow Us
Jenscare Scientific Co. Ltd. Class H (HK:9877)
:9877
9877 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.40 - HK$9.36
Previous CloseN/A
Volume216.80K
Average Volume (3M)135.73K
Market Cap
HK$2.63B
Enterprise ValueHK$816.06M
Total Cash (Recent Filing)¥727.36M
Total Debt (Recent Filing)¥3.87M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Sep 02, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding310,306,200
10 Day Avg. Volume129,380
30 Day Avg. Volume135,733
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Jenscare Scientific Co. Ltd. Class H News
PremiumCompany Announcements
Jenscare Scientific Announces Board Composition and Roles
PremiumCompany Announcements
Jenscare Scientific Schedules Board Meeting to Approve Annual Results
PremiumCompany Announcements
Jenscare Scientific Appoints New CEO to Drive Global StrategyPremiumCompany Announcements
Jenscare Scientific Passes Key Resolution at 2025 First EGM
PremiumCompany Announcements
Jenscare Scientific Sets Dates for Key 2025 Meeting---
9877 FAQ
What was Jenscare Scientific Co. Ltd. Class H’s price range in the past 12 months?
Jenscare Scientific Co. Ltd. Class H lowest stock price was HK$1.40 and its highest was HK$9.36 in the past 12 months.
What is Jenscare Scientific Co. Ltd. Class H’s market cap?
Jenscare Scientific Co. Ltd. Class H’s market cap is HK$2.63B.
When is Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date?
Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date is Sep 02, 2025 which is in 159 days.
How were Jenscare Scientific Co. Ltd. Class H’s earnings last quarter?
Jenscare Scientific Co. Ltd. Class H released its earnings results on Mar 21, 2025. The company reported -HK$0.192 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.192.
Is Jenscare Scientific Co. Ltd. Class H overvalued?
According to Wall Street analysts Jenscare Scientific Co. Ltd. Class H’s price is currently Overvalued.
Does Jenscare Scientific Co. Ltd. Class H pay dividends?
Jenscare Scientific Co. Ltd. Class H does not currently pay dividends.
What is Jenscare Scientific Co. Ltd. Class H’s EPS estimate?
Jenscare Scientific Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jenscare Scientific Co. Ltd. Class H have?
Jenscare Scientific Co. Ltd. Class H has 310,306,200 shares outstanding.
What happened to Jenscare Scientific Co. Ltd. Class H’s price movement after its last earnings report?
Jenscare Scientific Co. Ltd. Class H reported an EPS of -HK$0.192 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.743%.
Which hedge fund is a major shareholder of Jenscare Scientific Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9877
---
Jenscare Scientific Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.73%
12-Months-Change
Fundamentals
Return on Equity
-16.39%
Trailing 12-Months
Asset Growth
-25.16%
Trailing 12-Months
Company Description
Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of invasive interventional therapies for structural heart diseases in the People's Republic of China. The company offers LuX-Valve, a transcatheter tricuspid valve replacement (TTVR) product candidate for the treatment of severe tricuspid regurgitation and high surgical risk; and Ken-Valve, a transcatheter aortic valve replacement product candidate for the treatment of severe aortic regurgitation or combined with aortic stenosis. Its products have applications in the treatment of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases, and heart failure. The company was incorporated in 2011 and is headquartered in Ningbo, the People's Republic of China.
---
9877 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
CSPC Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Fujikon Industrial Holdings Limited
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Haohai Biological Technology Co., Ltd. Class H
―
---